JP2019504105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504105A5 JP2019504105A5 JP2018540862A JP2018540862A JP2019504105A5 JP 2019504105 A5 JP2019504105 A5 JP 2019504105A5 JP 2018540862 A JP2018540862 A JP 2018540862A JP 2018540862 A JP2018540862 A JP 2018540862A JP 2019504105 A5 JP2019504105 A5 JP 2019504105A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tumor
- composition
- administration
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022192529A JP7597452B2 (ja) | 2016-02-05 | 2022-12-01 | 中枢神経系のがんの治療のための組換えｔ細胞の投与 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662292152P | 2016-02-05 | 2016-02-05 | |
| US62/292,152 | 2016-02-05 | ||
| US201662309348P | 2016-03-16 | 2016-03-16 | |
| US62/309,348 | 2016-03-16 | ||
| PCT/US2017/016711 WO2017136829A1 (en) | 2016-02-05 | 2017-02-06 | Administration of engineered t cells for treatment of cancers in the central nervous system |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022192529A Division JP7597452B2 (ja) | 2016-02-05 | 2022-12-01 | 中枢神経系のがんの治療のための組換えｔ細胞の投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019504105A JP2019504105A (ja) | 2019-02-14 |
| JP2019504105A5 true JP2019504105A5 (https=) | 2020-03-19 |
| JP7189019B2 JP7189019B2 (ja) | 2022-12-13 |
Family
ID=59496551
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018540862A Active JP7189019B2 (ja) | 2016-02-05 | 2017-02-06 | 中枢神経系の癌の治療のための操作されたｔ細胞の投与 |
| JP2022192529A Active JP7597452B2 (ja) | 2016-02-05 | 2022-12-01 | 中枢神経系のがんの治療のための組換えｔ細胞の投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022192529A Active JP7597452B2 (ja) | 2016-02-05 | 2022-12-01 | 中枢神経系のがんの治療のための組換えｔ細胞の投与 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20170224733A1 (https=) |
| EP (2) | EP3411393B1 (https=) |
| JP (2) | JP7189019B2 (https=) |
| KR (1) | KR20180105709A (https=) |
| CN (1) | CN108779160A (https=) |
| AU (2) | AU2017213661B2 (https=) |
| BR (1) | BR112018015836A2 (https=) |
| CA (1) | CA3013773A1 (https=) |
| DK (1) | DK3411393T3 (https=) |
| ES (1) | ES2879700T3 (https=) |
| IL (2) | IL287889B2 (https=) |
| MX (1) | MX2023006304A (https=) |
| RU (1) | RU2757308C2 (https=) |
| WO (1) | WO2017136829A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934532B1 (en) | 2012-12-20 | 2019-10-23 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| CA2945320A1 (en) | 2014-04-10 | 2015-10-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Drug regulated transgene expression |
| WO2017027291A1 (en) | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
| ES2879700T3 (es) | 2016-02-05 | 2021-11-22 | Hope City | Administración de células T genomanipuladas para el tratamiento de cánceres en el sistema nervioso central |
| JP7282521B2 (ja) | 2016-04-08 | 2023-05-29 | パーデュー・リサーチ・ファウンデイション | Ｃａｒ ｔ細胞療法のための方法および組成物 |
| CN110291200B (zh) | 2016-12-12 | 2024-05-14 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体 |
| JP7178355B2 (ja) | 2017-02-28 | 2022-11-25 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための組成物および方法 |
| CN109971725B (zh) * | 2017-12-28 | 2024-02-02 | 上海细胞治疗研究院 | 抗体修饰的嵌合抗原受体修饰t细胞及其用途 |
| JP7549303B2 (ja) | 2018-01-22 | 2024-09-11 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞の使用方法 |
| CN112105382A (zh) | 2018-02-23 | 2020-12-18 | 恩多塞特公司 | 用于car t细胞疗法的顺序方法 |
| WO2019178078A1 (en) | 2018-03-14 | 2019-09-19 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy |
| SG11202008926RA (en) * | 2018-03-14 | 2020-10-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy |
| US20190284553A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| WO2019232523A1 (en) * | 2018-06-01 | 2019-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof |
| US12419954B2 (en) | 2020-01-31 | 2025-09-23 | City Of Hope | Targeted chimeric antigen receptor modified T cells for treatment of IL13Rα2 positive malignancies |
| WO2021202799A2 (en) | 2020-03-31 | 2021-10-07 | Fred Hutchinson Cancer Research Center | Chimeric antigen receptors targeting cd33 |
| WO2021202793A2 (en) * | 2020-03-31 | 2021-10-07 | Fred Hutchinson Cancer Research Center | Chimeric antigen receptors targeting cd33 |
| CN113646433B (zh) * | 2020-07-16 | 2022-10-11 | 苏州博腾生物制药有限公司 | 靶向抗TNF-α抗体的组合物和方法 |
| EP4247850A1 (en) | 2020-11-20 | 2023-09-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
| WO2022212525A2 (en) * | 2021-03-30 | 2022-10-06 | City Of Hope | Car t cell therapy and ifn gamma |
| WO2025235801A1 (en) | 2024-05-08 | 2025-11-13 | City Of Hope | Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7514537B2 (en) * | 2001-04-30 | 2009-04-07 | City Of Hope | Chimeric immunoreceptor useful in treating human gliomas |
| US11278594B2 (en) | 2001-04-30 | 2022-03-22 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| CA2682527C (en) * | 2007-03-30 | 2017-07-11 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
| EP4032552B1 (en) * | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| WO2011059836A2 (en) * | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| EP2640404B1 (en) * | 2010-11-17 | 2017-02-22 | Ben Gurion University of The Negev Research and Development Authority | T-cell therapy to neurodegenerative diseases |
| AU2013302406B2 (en) * | 2012-08-17 | 2018-05-17 | Memorial Sloan-Kettering Cancer Center | Gene expression profile associated with prostate cancer |
| AU2013337926B2 (en) * | 2012-10-30 | 2017-12-21 | Esperance Pharmaceuticals, Inc. | Antibody/drug conjugates and methods of use |
| AU2013204922B2 (en) * | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| US20160333108A1 (en) * | 2014-01-13 | 2016-11-17 | Stephen J. Forman | CHIMERIC ANTIGEN RECEPTORS (CARs) HAVING MUTATIONS IN THE FC SPACER REGION AND METHODS FOR THEIR USE |
| KR20160145802A (ko) * | 2014-04-23 | 2016-12-20 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법 |
| WO2017027291A1 (en) * | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
| CN105131126B (zh) * | 2015-10-10 | 2019-02-01 | 北京康爱瑞浩细胞技术有限公司 | 用于治疗恶性肿瘤的嵌合抗原受体及其制备方法与应用 |
| CA3001833A1 (en) | 2015-10-13 | 2017-04-20 | City Of Hope | Chimeric antigen receptors containing a chlorotoxin domain |
| EP4074731A1 (en) * | 2015-11-04 | 2022-10-19 | City of Hope | Chimeric antigen receptors targeting her2 |
| ES2879700T3 (es) | 2016-02-05 | 2021-11-22 | Hope City | Administración de células T genomanipuladas para el tratamiento de cánceres en el sistema nervioso central |
| US12419954B2 (en) | 2020-01-31 | 2025-09-23 | City Of Hope | Targeted chimeric antigen receptor modified T cells for treatment of IL13Rα2 positive malignancies |
| US20230374085A1 (en) | 2020-03-11 | 2023-11-23 | City Of Hope | Dual-targeting chimeric antigen receptor modified t cells comprising il-13 and chlorotoxin for cancer treatment |
| CN115515971A (zh) | 2020-03-12 | 2022-12-23 | 希望之城公司 | 治疗IL13Rα2阳性恶性病的靶向性嵌合抗原受体修饰的T细胞 |
| CA3194747A1 (en) | 2020-09-10 | 2022-03-17 | Mustang Bio, Inc. | Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer |
-
2017
- 2017-02-06 ES ES17748349T patent/ES2879700T3/es active Active
- 2017-02-06 WO PCT/US2017/016711 patent/WO2017136829A1/en not_active Ceased
- 2017-02-06 IL IL287889A patent/IL287889B2/en unknown
- 2017-02-06 DK DK17748349.2T patent/DK3411393T3/da active
- 2017-02-06 CN CN201780017442.9A patent/CN108779160A/zh active Pending
- 2017-02-06 BR BR112018015836-4A patent/BR112018015836A2/en active Search and Examination
- 2017-02-06 EP EP17748349.2A patent/EP3411393B1/en active Active
- 2017-02-06 RU RU2018130752A patent/RU2757308C2/ru active
- 2017-02-06 KR KR1020187025196A patent/KR20180105709A/ko not_active Ceased
- 2017-02-06 EP EP21166981.7A patent/EP3912993A1/en not_active Withdrawn
- 2017-02-06 AU AU2017213661A patent/AU2017213661B2/en active Active
- 2017-02-06 CA CA3013773A patent/CA3013773A1/en active Pending
- 2017-02-06 US US15/425,773 patent/US20170224733A1/en not_active Abandoned
- 2017-02-06 JP JP2018540862A patent/JP7189019B2/ja active Active
-
2018
- 2018-08-01 IL IL260930A patent/IL260930B/en unknown
- 2018-08-03 MX MX2023006304A patent/MX2023006304A/es unknown
-
2020
- 2020-09-18 US US17/025,723 patent/US12472233B2/en active Active
-
2022
- 2022-09-02 AU AU2022224866A patent/AU2022224866A1/en not_active Abandoned
- 2022-12-01 JP JP2022192529A patent/JP7597452B2/ja active Active
-
2025
- 2025-10-07 US US19/351,506 patent/US20260027181A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504105A5 (https=) | ||
| Pol et al. | Trial watch: oncolytic viruses for cancer therapy | |
| MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| BR112018074192A8 (pt) | Método para tratamento de um sujeito, método para produzir uma composição celular, composição de células, composição de vacina e kit | |
| JP2016535009A5 (https=) | ||
| TW202428301A (zh) | 治療性rna | |
| RU2017126610A (ru) | Терапевтические композиции и способы против злокачественных опухолей с молекулами рнки, направленными против hsp47 | |
| JP2018502120A5 (https=) | ||
| JP2020510624A5 (https=) | ||
| EA201490911A1 (ru) | Способы лечения злокачественных опухолей с использованием пероральных составов аналогов цитидина | |
| JP2016528162A5 (https=) | ||
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| Shou et al. | Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy | |
| Helm et al. | Combining heavy-ion therapy with immunotherapy: an update on recent developments | |
| WO2021182573A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| PH12015502260A1 (en) | C. novyi for the treatment of solid tumors in humans | |
| Wu et al. | Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma | |
| WO2021159035A1 (en) | Oncolytic virus compositions and methods for the treatment of cancer | |
| MX2019005104A (es) | Composiciones de zinc-y-pga y métodos para tratar el cancer. | |
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| Sai et al. | Basic and translational research on carbon-ion radiobiology | |
| Xia et al. | Nanobody engineered and photosensitiser loaded bacterial outer membrane vesicles potentiate antitumour immunity and immunotherapy | |
| He et al. | Role of tumor-associated macrophages in breast cancer immunotherapy | |
| Sun et al. | Combining immunotherapy with radiotherapy for glioblastoma: recent advances and challenges | |
| Marcu | Improving Therapeutic Ratio in Head and Neck Cancer with Adjuvant and Cisplatin‐Based Treatments |